EUVIMEDEUVIMED entdecken
Crossref

Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage‐Nucleus Pulposus Cell Crosstalk

Chen-Cheng Zhou, Cheng-Long Xie, Xiang-Cheng Zhang, Zhuo-Fan Zeng, Yi-Feng Shi, Yi-Tian Yu, Su-Yu Ying, Yu-Rui Wu, Zi-Han Dai, Wen-Tian Cao, Hai-Wei Ma, Gang Zheng

British Journal of Pharmacology · 2026-05 · 183 (10) · 2406-2428

DOI: 10.1111/bph.70283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 15.01.2026. Verfasst von Chen-Cheng Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Orthopaedics of Zhejiang Province, Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wen…. Hauptthemen laut MEDLINE: Macrophages, Sitagliptin Phosphate, Dipeptidyl-Peptidase IV Inhibitors, Nucleus Pulposus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Wenzhou Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Intervertebral disc degeneration (IVDD), a leading cause of low back pain, lacks effective disease‐modifying therapies. Diabetes exacerbates IVDD risk, but the causal mechanisms and therapeutic potential of glucose‐lowering agents remain underexplored. This study aimed to identify glucose‐lowering drug targets strongly associated with IVDD using Mendelian randomisation (MR) and to validate the therapeutic efficacy and mechanisms of sitagliptin, an inhibitor of dipeptidyl peptidase 4 (DPP4), in alleviating IVDD progression. Experimental approach Two‐sample MR analysis was performed to assess causal links between glucose‐lowering drug targets and IVDD risk using genome‐wide association studies data. A tail puncture model in male SD rats, interactive culture systems of nucleus pulposus (NP) cells and macrophages were established to evaluate effects of sitagliptin. Molecular techniques and network pharmacology were employed to elucidate mechanisms. Key results MR analysis identified DPP4 as a causal risk factor for IVDD. DPP4 expression was elevated in degenerated human and rat NP tissues. Sitagliptin alleviated disc height loss, preserved extracellular matrix (ECM) integrity, and reduced histological degeneration in vivo. Sitagliptin suppressed macrophage infiltration and interfered with polarisation. It disrupted the NF‐κB/NLRP3/IL‐1β axis in NP cells, attenuating inflammasome activation, pro‐inflammatory cytokine release and ECM degradation. Conclusion and implications DPP4 was a causal driver of IVDD, and its inhibition by sitagliptin mitigated degeneration by disrupting the pathogenic positive feedback loop between macrophages and NP cells. These findings reposition sitagliptin, a clinically approved antidiabetic drug, as a promising therapeutic candidate for IVDD, highlighting the translational potential of targeting DPP4 and its downstream inflammatory cascades.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MacrophagesSitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsNucleus PulposusIntervertebral Disc DegenerationDipeptidyl Peptidase 4Hypoglycemic AgentsAnimalsMaleHumansRatsRats, Sprague-DawleyInterleukin-1beta

Stichwörter der Autor:innen

DPP4IVDDMendelian randomisationnucleus pulposussitagliptin

Substanzen

Sitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4Hypoglycemic AgentsInterleukin-1betaDPP4 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Orthopaedics of Zhejiang Province, Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • The Second Affiliated Hospital and Yuying Children''s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
  • Department of Orthopaedics Surgery, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, Zhejiang Province, China.

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • Wenzhou Medical University
  • National Natural Science Foundation of China
  • Medicine and Health Project of Zhejiang Province
  • Wenzhou Major Science and Technology Innovation Breakthrough Project
  • National Innovation and Entrepreneurship Training Program for College Students

Zitieren

APA

Zhou, C. C., Xie, C. L., Zhang, X. C., Zeng, Z. F., Shi, Y. F., Yu, Y. T., Ying, S. Y., Wu, Y. R., Dai, Z. H., Cao, W. T., Ma, H. W., & Zheng, G. (2026). Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage‐Nucleus Pulposus Cell Crosstalk. British Journal of Pharmacology, 183(10), 2406-2428. https://doi.org/10.1111/bph.70283

Vancouver

Zhou CC, Xie CL, Zhang XC, Zeng ZF, Shi YF, Yu YT, et al. Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage‐Nucleus Pulposus Cell Crosstalk. British Journal of Pharmacology. 2026;183(10):2406-2428. doi:10.1111/bph.70283

BibTeX
@article{Zhou2026,
  author = {Zhou, Chen-Cheng and Xie, Cheng-Long and Zhang, Xiang-Cheng and Zeng, Zhuo-Fan and Shi, Yi-Feng and Yu, Yi-Tian and Ying, Su-Yu and Wu, Yu-Rui and Dai, Zi-Han and Cao, Wen-Tian and Ma, Hai-Wei and Zheng, Gang},
  title = {Antidiabetic DPP4 inhibitor Attenuates Intervertebral Disc Degeneration via Macrophage‐Nucleus Pulposus Cell Crosstalk},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {10},
  pages = {2406--2428},
  doi = {10.1111/bph.70283}
}
Kostenlos starten →